CoChat

Therapeutics Targeting the Core Apoptotic Machinery

Open access

The DOI matches its Crossref record; 181 of the 185 references it cites were found in a registry or an index.

Abstract

Therapeutic targeting of the apoptotic pathways for the treatment of cancer is emerging as a valid and exciting approach in anti-cancer therapeutics. Accumulating evidence demonstrates that cancer cells are typically “addicted” to a small number of anti-apoptotic proteins for their survival, and direct targeting of these proteins could provide valuable approaches for directly killing cancer cells. Several approaches and agents are in clinical development targeting either the intrinsic mitochondrial apoptotic pathway or the extrinsic death receptor mediated pathways. In this review, we discuss the main apoptosis pathways and the key molecular targets which are the subject of several drug development approaches, the clinical development of these agents and the emerging resistance factors and combinatorial treatment approaches for this class of agents with existing and emerging novel targeted anti-cancer therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13112618

Cites

181 of 181 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Intrinsic apoptotic pathway. In the intrinsic pathway, internal stresses such as DNA damage can lead to the B-cell lymphoma family-2 homology domain -3 (BH3) sensor proteins being activated and inhibiting anti-apoptotic B-cell lymphoma family-2 (BCL-2) proteins, leading to oligomerisation and activation of BCL-2 associated X protein (BAX)and BCL-2 antagonist killer 1 (BAK) and the formation of pores in the outer mitochondrial membrane. Mitochondrial outer membrane permeabilization (MOMP) releases cytochrome c and second mitochondrial activator of caspase (SMAC). Cytochrome c forms a complex with apoptotic protease-activating factor 1 (APAF1) and pro-caspase-9, termed the apoptosome, in which procaspase-9 dimerises and becomes activated triggering the activation of a caspase cascade. The active caspase-9 heterodimer cleaves and activates the apoptotic effector caspases -3 and -7. SMAC inhibits X-linked inhibitor of apoptosis (XIAP) to facilitate activation of procaspase-3 and -7. Created with BioRender.com (accessed on 25 May 2021).
Figure 1 Intrinsic apoptotic pathway. In the intrinsic pathway, internal stresses such as DNA damage can lead to the B-cell lymphoma family-2 homology domain -3 (BH3) sensor proteins being activated and inhibiting anti-apoptotic B-cell lymphoma family-2 (BCL-2) proteins, leading to oligomerisation and activation of BCL-2 associated X protein (BAX)and BCL-2 antagonist killer 1 (BAK) and the formation of pores in the outer mitochondrial membrane. Mitochondrial outer membrane permeabilization (MOMP) releases cytochrome c and second mitochondrial activator of caspase (SMAC). Cytochrome c forms a complex with apoptotic protease-activating factor 1 (APAF1) and pro-caspase-9, termed the apoptosome, in which procaspase-9 dimerises and becomes activated triggering the activation of a caspase cascade. The active caspase-9 heterodimer cleaves and activates the apoptotic effector caspases -3 and -7. SMAC inhibits X-linked inhibitor of apoptosis (XIAP) to facilitate activation of procaspase-3 and -7. Created with BioRender.com (accessed on 25 May 2021).CC BY · PubMed Central
Figure 2 The extrinsic apoptosis pathway. The death receptor-mediated extrinsic apoptosis pathway is initiated following ligand binding to a trimeric death receptor. In the case of Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) binding the TRAIL receptor (TRAIL-R) the adaptor protein, Fas-associated death domain (FADD), is recruited to the death receptor via homotypic death domain interactions. FADD subsequently recruits procaspase-8 through interactions of their respective death effector domains, forming the death inducing signaling complex (DISC). Procaspase-8 dimerizes and is activated to release the active caspase-8 homodimer. FADD-like IL1β-converting enzyme inhibitory protein (FLIP) can also be recruited to the DISC where it can modulate the activation of caspase-8. In Type I cells, caspase-8 directly activates effector procaspase-3 and -7. In type II cells, apoptosis depends on caspase-8-mediated cleavage of BH3-interacting domain death agonist (BID). Activated tBID translocates to the mitochondria to induce BCL-2 associated X protein (BAX)/ BCL-2 antagonist killer 1 (BAK) mediated mitochondrial outer membrane permeabilization (MOMP). Subsequent second mitochondrial activator of caspase (SMAC) release neutralizes X-linked inhibitor of apoptosis (XIAP) and permits the final auto-catalytic step in the activation of caspases-3/7. Created with BioRender.com (accessed on 25 May 2021).
Figure 2 The extrinsic apoptosis pathway. The death receptor-mediated extrinsic apoptosis pathway is initiated following ligand binding to a trimeric death receptor. In the case of Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) binding the TRAIL receptor (TRAIL-R) the adaptor protein, Fas-associated death domain (FADD), is recruited to the death receptor via homotypic death domain interactions. FADD subsequently recruits procaspase-8 through interactions of their respective death effector domains, forming the death inducing signaling complex (DISC). Procaspase-8 dimerizes and is activated to release the active caspase-8 homodimer. FADD-like IL1β-converting enzyme inhibitory protein (FLIP) can also be recruited to the DISC where it can modulate the activation of caspase-8. In Type I cells, caspase-8 directly activates effector procaspase-3 and -7. In type II cells, apoptosis depends on caspase-8-mediated cleavage of BH3-interacting domain death agonist (BID). Activated tBID translocates to the mitochondria to induce BCL-2 associated X protein (BAX)/ BCL-2 antagonist killer 1 (BAK) mediated mitochondrial outer membrane permeabilization (MOMP). Subsequent second mitochondrial activator of caspase (SMAC) release neutralizes X-linked inhibitor of apoptosis (XIAP) and permits the final auto-catalytic step in the activation of caspases-3/7. Created with BioRender.com (accessed on 25 May 2021).CC BY · PubMed Central
Figure 3 B-cell lymphoma family-2 (BCL-2) Family Members. Family members of the BCL-2 protein family comprising: (i) B-cell lymphoma family-2 homology domain -3 (BH3)-only pro-apoptotic initiating proteins; (ii) the anti-apoptotic family members that protect against apoptosis by inhibiting the BH3-only proteins or neutralising the effector proteins directly; and (iii) the pro-apoptotic effector proteins which once activated trigger mitochondrial outer membrane permeabilization (MOMP), releasing apoptogenic factors from the mitochondria, leading to caspase activation and apoptosis. Listed are the agents developed to target specifically the indicated target(s).
Figure 3 B-cell lymphoma family-2 (BCL-2) Family Members. Family members of the BCL-2 protein family comprising: (i) B-cell lymphoma family-2 homology domain -3 (BH3)-only pro-apoptotic initiating proteins; (ii) the anti-apoptotic family members that protect against apoptosis by inhibiting the BH3-only proteins or neutralising the effector proteins directly; and (iii) the pro-apoptotic effector proteins which once activated trigger mitochondrial outer membrane permeabilization (MOMP), releasing apoptogenic factors from the mitochondria, leading to caspase activation and apoptosis. Listed are the agents developed to target specifically the indicated target(s).CC BY · PubMed Central
Figure 4 Timeline of progress in therapeutics targeting the apoptotic core machinery. This figure summarizes some of the major advances in the development of different therapeutic agents targeting key anti-apoptotic proteins from the early 1980’s to the current time. Abbreviations:B-cell lymphoma family (BCL-2), BCL-2 associated X protein (BCL-XL), B-cell lymphoma-w (BCL-W), BCL-2 homology domain-3 (BH3), Chronic Lymphocytic leukaemia (CLL), Circularly permuted TRAIL (CPT), Death receptor (DR), US Food and Drug Administration (FDA), Fas-associated death domain (FADD)-like IL1β-converting enzyme-inhibitory protein (FLIP), messenger RNA (mRNA), Second mitochondria-derived activator of caspases (SMAC), Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
Figure 4 Timeline of progress in therapeutics targeting the apoptotic core machinery. This figure summarizes some of the major advances in the development of different therapeutic agents targeting key anti-apoptotic proteins from the early 1980’s to the current time. Abbreviations:B-cell lymphoma family (BCL-2), BCL-2 associated X protein (BCL-XL), B-cell lymphoma-w (BCL-W), BCL-2 homology domain-3 (BH3), Chronic Lymphocytic leukaemia (CLL), Circularly permuted TRAIL (CPT), Death receptor (DR), US Food and Drug Administration (FDA), Fas-associated death domain (FADD)-like IL1β-converting enzyme-inhibitory protein (FLIP), messenger RNA (mRNA), Second mitochondria-derived activator of caspases (SMAC), Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 181 references

Research works printed but not linked: 1

  1. (2019, September 12). Amgen News Release. Available online: https://www.amgen.com/newsroom/press-releases/2019/09/amgen-highlights-new-data-from-kyprolis-carfilzomib-and-oncology-pipeline-at-imw-2019.

Cited by

See all 30

Metadata

Authors
Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A.
Affiliations
Queen's University Belfast (GB)
Corresponding author
Higgins, Catherine A.
Venue
Cancers
Publisher
MDPI AG
Published
2021-05-26
Volume
13
Issue
11
Pages
2618
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3164877207
Cited by
26
References
185
Citations by year
2026: 6 · 2025: 5 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 3
FWCI
0.39
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (Queen's University Belfast) (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Wellcome Trust (110371/Z/15/Z)
  • Cancer Research UK (24387)
  • Medical Research Council (MR/S021205/1)
  • Biotechnology and Biological Sciences Research Council (BB/T002824/1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Pharmacology (medical) › Flavonoids in Medical Research
Keywords
apoptosis, cancer therapy, anti-apoptotic proteins, intrinsic mitochondrial apoptotic pathway, extrinsic death receptor pathway, targeted cancer therapy, drug resistance, combination therapy, clinical development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutics Targeting the Core Apoptotic Machinery. https://app.cochat.ai/papers/10.3390/cancers13112618
The paper
Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021). Therapeutics Targeting the Core Apoptotic Machinery. Cancers. https://doi.org/10.3390/cancers13112618

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.